Cargando…
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
BACKGROUND: The reimbursement for expensive medicines poses a growing challenge to healthcare worldwide. In order to increase its control over the costs of medicines, the Dutch government introduced the Coverage Lock (CL) policy in 2015. The CL postpones decisions regarding reimbursement of expensiv...
Autores principales: | Scheijmans, Féline E. V., Zomers, Margot L., Fadaei, Sina, Onrust, Marthe R., van der Graaf, Rieke, Delden, Johannes J. M. van, van der Pol, W. Ludo, van Thiel, Ghislaine J. M. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636634/ https://www.ncbi.nlm.nih.gov/pubmed/36333803 http://dx.doi.org/10.1186/s12913-022-08690-z |
Ejemplares similares
-
A human rights-based approach to the reimbursement of expensive medicines
por: Perehudoff, Katrina, et al.
Publicado: (2016) -
Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study
por: Scheijmans, Féline E V, et al.
Publicado: (2022) -
Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021) -
Lifelong versus not lifelong death wishes in older adults without severe illness: a cross-sectional survey
por: Elzinga, Elke, et al.
Publicado: (2022) -
Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)